Tissue distribution of the Ankara strain of vaccinia virus (MVA) after mucosal or systemic administration.
MVA is a candidate vector for vaccination against pathogens and tumors. Little is known about its behaviour in mucosal tissues. We have investigated the fate and biosafety of MVA, when inoculated by different routes in C57BL/6 mice. Intranasal inoculation targeted the virus to the nasal associated lymphoid tissue and the lungs, whereas systemic inoculation led to distribution of MVA in almost all lymphoid organs, lungs and ovaries. Intravaginal, intrarectal and intragastric inoculations failed to induce efficient infection. After 48 h no virus was detectable any more in the organs analyzed. Upon intranasal inoculation, no inflammatory reactions were detected in the central nervous system as well as the upper and lower airways. These results show the tropism of MVA and indicate that high doses of recombinant MVA are safe when nasally administered, a vaccination route known to elicit strong cellular and humoral immune responses in the female genital tract.
Centro Nacional de Biotecnología, CSIC, Campus Universidad Autonoma de Madrid, Spain.
J C
JC
Ramirez
D
D
Finke
M
M
Esteban
J P
JP
Kraehenbuhl
H
H
Acha-Orbea
D000281:Administration, Intranasal; D000818:Animals; D001921:Brain / Q000821:virology; D004064:Digestive System / Q000821:virology*; D005260:Female; D005836:Genitalia, Female / Q000821:virology*; D018928:Immunity, Mucosal / Q000276:immunology; D008168:Lung / Q000821:virology; D008198:Lymph Nodes / Q000821:virology*; D051379:Mice; D008810:Mice, Inbred C57BL; D009092:Mucous Membrane / Q000821:virology*; D012137:Respiratory System / Q000821:virology*; D014612:Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000145:classification* / Q000276:immunology; D014616:Vaccinia virus / Q000145:classification* / Q000276:immunology / Q000302:isolation & purification*
D014612:Vaccines